UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN) announced its participation in the 45th Annual Goldman Sachs Global Healthcare Conference. The event will occur in Miami, FL, from June 10-13, 2024, and UroGen's management will present on June 11 at 3:20 PM ET. The presentation will be in a fireside chat format. A webcast will be available live and for replay for approximately 90 days on the company's investor relations website.

Positive

• UroGen Pharma's participation in a high-profile healthcare conference could increase visibility and investor interest.
• Webcast availability allows broader access to the presentation, potentially enhancing investor engagement.

Negative

• The announcement lacks specific new clinical or financial data that could directly impact stock valuation.
• There's no mention of new product launches or significant business developments.

- Presentation June 11, 2024 at 3:20 PM ET -

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45^th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024.

Goldman Sachs 45th Annual Healthcare Conference
Date/ time:		June 11, 2024 at 3:20 PM ET
Format:		Fireside Chat
Location:		Miami, FL
Webcast Link:		here

A webcast from the conference will also be available via the Investors section of UroGen’s corporate website, https://investors.urogen.com. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605807048/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma present at the Goldman Sachs Global Healthcare Conference?

UroGen Pharma will present on June 11, 2024, at 3:20 PM ET.

Where is the 45th Annual Goldman Sachs Global Healthcare Conference held?

The conference will take place in Miami, FL, from June 10-13, 2024.

What format will UroGen Pharma's presentation take?

The presentation will be in a fireside chat format.

How can investors view UroGen Pharma's presentation?

A webcast will be available live and for replay for approximately 90 days on UroGen Pharma’s investor relations website.

What is the stock symbol for UroGen Pharma?

UroGen Pharma trades under the stock symbol URGN on Nasdaq.